Opticon delays launch of clinical trial:
This article was originally published in Clinica
Executive Summary
Opticon Medical has delayed a pivotal clinical trial of its urinary catheter, the Option-vf, in order to implement an "engineering change" to a feature of the device, says the company. Opticon president William Post said that the delay in patient enrolment in exchange for the latest technology is "worth the trade off". Last year, the Dublin, Ohio-based company reported promising results from a pilot study of the Option-vf, which is designed for the short-term management of urinary retention following lower urinary tract surgery (see Clinica No 923, p 17).
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.